Catalyst Biosciences, Inc.: Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5

Related Keywords

China ,Ying Luo ,Liaoning ,Beijing ,Japan ,Tokyo ,United States ,Canada ,Chinese ,Trisha Colton ,Nassim Usman ,Augustine Lawlor ,Raymond James ,Thomas Eastling ,Gibson ,Catalyst Biosciences Inc ,Nasdaq ,Group Ltd ,Group In Subsequent Transaction ,Dunn Crutcher ,Securities Exchange ,Company Or Catalyst ,Leadership Organization ,Herrington Sutcliffe ,Pharma Company ,Acquire Controlling Interest ,China Based Commercial Pharma Company ,Special Dividend ,Contingent Value Right ,Meeting Planned ,Host Conference Call Today ,Beijing Continent ,Mainland China ,Catalyst Board ,Andrea Hunt ,Seline Miller ,Chief Executive Officer ,Interim Chief Financial Officer ,Seriesx Preferred Stock ,Preferred Stock ,Business Combination ,Business Combination Agreement ,Catalyst Common Stock ,Catalyst Biosciences ,Securities Exchange Act ,Securities Act ,Minority Holders ,Annual Report ,Quarterly Reports ,Current Reports ,Additional Information Will ,Catalyst ,Iosciences ,Ompletes ,First ,Steps ,Reverse ,Berger ,Plan ,